[
  {
    "sentence": "Most included studies (30) were published after 2017, the year of publication of the prior SLR by Waziry et al. [5] The PRISMA flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Most included studies (30) were published after 2017, the year of publication of the prior SLR by Waziry et al. [5] The PRISMA flow diagram is presented in Fig. 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 1.29 [95% CI 0.69, 2.40] (Fig. 2), indicating no difference between DAA and IFN with considerable statistical heterogeneity (I2 statistic 66.6%) and imprecision (i.e., wide confidence interval).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.88 [95% CI 0.56, 1.39] (Fig. 3), indicating no difference between DAA and IFN with substantial statistical heterogeneity (I2 statistic 77.8%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.67 [95% CI 0.51, 0.88] (Fig. 4), indicating favorable results for DAA therapy compared with IFN with considerable statistical heterogeneity (I2 statistic 78.7%).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Three studies (374 patients) compared IFN-free DAA regimens versus no DAA (as reported by study authors as not receiving DAAs with no indication whether IFN or another antiviral therapy was administered, or no antiviral therapy was administered) at 12 months (Fig. 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.55 [95% CI 0.25, 1.23] (Fig. 2), indicating favorable results for DAA therapy compared with no DAA therapy with considerable statistical heterogeneity (I2 statistic 65.7%).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.67 [95% CI 0.51, 0.86] (Fig. 3), indicating favorable results for DAA compared with no DAA with no statistical heterogeneity (I2 statistic 0.0%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.72 [95% CI 0.61, 0.85] (Fig. 4), indicating favorable results for DAA compared with no DAA and low statistical heterogeneity (I2 statistic 15.9%).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.95 [95% CI 0.76, 1.20] (Fig. 2), indicating no difference between DAA and no antiviral therapy and no statistical heterogeneity (I2 statistic 0.0%).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.48 [95% CI 0.11, 2.12] (Fig. 3), indicating no difference between DAA and no antiviral therapy with possible considerable heterogeneity (I2 statistic 97.3%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The combined RR for HCC recurrence was 0.42 [95% CI 0.24, 0.73] (Fig. 4), indicating favorable results for DAA compared with no antiviral therapy with considerable heterogeneity (I2 statistic 90.8%).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]